KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Novartis Ag (NVS) Receivables Refunds (2016 - 2026)

Novartis Ag's Receivables Refunds history spans 11 years, with the latest figure at $216.0 million for Q1 2026.

  • On a quarterly basis, Receivables Refunds rose 67.44% to $216.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $216.0 million, a 67.44% increase, with the full-year FY2025 number at $205.0 million, up 54.14% from a year prior.
  • Receivables Refunds hit $216.0 million in Q1 2026 for Novartis Ag, up from $205.0 million in the prior quarter.
  • Over the last five years, Receivables Refunds for NVS hit a ceiling of $426.0 million in Q4 2023 and a floor of $120.0 million in Q2 2025.
  • Historically, Receivables Refunds has averaged $245.5 million across 5 years, with a median of $258.0 million in 2022.
  • Biggest five-year swings in Receivables Refunds: tumbled 68.78% in 2024 and later skyrocketed 67.44% in 2026.
  • Tracing NVS's Receivables Refunds over 5 years: stood at $268.0 million in 2022, then soared by 58.96% to $426.0 million in 2023, then tumbled by 68.78% to $133.0 million in 2024, then surged by 54.14% to $205.0 million in 2025, then increased by 5.37% to $216.0 million in 2026.
  • Business Quant data shows Receivables Refunds for NVS at $216.0 million in Q1 2026, $205.0 million in Q4 2025, and $140.0 million in Q3 2025.